N-Cyano-N'-(2,3-dihydro-1H-inden-2-yl)-N''-[3-methoxy-4-(5-oxazolyl)-phenyl]guanidine | 441756-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-Cyano-N'-(2,3-dihydro-1H-inden-2-yl)-N''-[3-methoxy-4-(5-oxazolyl)-phenyl]guanidine
• 英文别名: N-Cyano-N'-(2,3-dihydro-1H-inden-2-yl)-N"-[3-methoxy-4-(5-oxazolyl)-phenyl]guanidine；1-cyano-2-(2,3-dihydro-1H-inden-2-yl)-3-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]guanidine
• CAS: 441756-61-2
• 化学式: C₂₁H₁₉N₅O₂
• 分子量: 373.414
• InChiKey: CJHKCBKLDSXCDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  95.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Angiogenesis inhibitors
  申请人：THE JOHNS-HOPKINS UNIVERSITY

  公开号：EP2803357A2

  公开（公告）日：2014-11-19

  Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

  本文描述了抑制血管生成和治疗或预防与血管生成有关的疾病或紊乱（或其症状）的方法，其中向受试者施用抗血管生成化合物。
• ANGIOGENESIS INHIBITORS
  申请人：THE JOHNS-HOPKINS UNIVERSITY

  公开号：EP1765336A2

  公开（公告）日：2007-03-28
• Metabolism-modulating agents and uses therefor
  申请人：Whitehead Paul Jonathan

  公开号：US20060106097A1

  公开（公告）日：2006-05-18

  The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5′ monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• Angiogenesis Inhibitors
  申请人：Liu Jun

  公开号：US20080193499A1

  公开（公告）日：2008-08-14

  Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
• US6420403B1
  申请人：——

  公开号：US6420403B1

  公开（公告）日：2002-07-16